{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:28:07Z","timestamp":1786987687346,"version":"build-2736575974"},"reference-count":27,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.diagmicrobio.2025.117110","type":"journal-article","created":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T16:27:06Z","timestamp":1757780826000},"page":"117110","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["High in vitro activity of Fosfomycin in carbapenemase-producing Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa in clinical isolates in Colombia"],"prefix":"10.1016","volume":"114","author":[{"given":"Elsa De La","family":"Cadena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Esparza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Carlos","family":"Garc\u00eda-Betancur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Restrepo-Arbel\u00e1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betsy E.","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian Jos\u00e9","family":"Pallares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0361-7893","authenticated-orcid":false,"given":"Mar\u00eda Virginia","family":"Villegas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0001","doi-asserted-by":"crossref","unstructured":"Mattioni Marchetti V., Hrabak J., Bitar I. Fosfomycin resistance mechanisms in enterobacterales: an increasing threat. Vol. 13, Frontiers in Cellular and Infection Microbiology. Frontiers Media SA; 2023.","DOI":"10.3389\/fcimb.2023.1178547"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.117110_bib0002","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/14787210.2020.1813023","article-title":"Update on the epidemiology of carbapenemases in Latin America and the Caribbean","volume":"19","author":"Garc\u00eda-Betancur","year":"2021","journal-title":"Expert Rev Anti Infect Ther"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0003","first-page":"363","volume":"23","author":"Grabein","year":"2017","journal-title":"Intravenous fosfomycin\u2014back to the future. Systematic review and meta-analysis of the clinical literature"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0004","first-page":"321","volume":"29","author":"Falagas","year":"2016"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0005","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jiac.2016.01.010","article-title":"Fosfomycin: resurgence of an old companion","volume":"22","author":"Sastry","year":"2016","journal-title":"J Infect Chemother"},{"issue":"9","key":"10.1016\/j.diagmicrobio.2025.117110_bib0006","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1128\/AAC.00349-11","article-title":"Antimicrobial susceptibilities of commonly encountered bacterial isolates to fosfomycin determined by agar dilution and disk diffusion methods","volume":"55","author":"Lu","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.117110_bib0007","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a025262","article-title":"Fosfomycin: mechanism and resistance","volume":"7","author":"Silver","year":"2017","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0008","doi-asserted-by":"crossref","unstructured":"Ito R., Mustapha M.M., Tomich A.D., Callaghan J.D., Mcelheny C.L., Mettus R.T., et al. Widespread fosfomycin resistance in gram-negative bacteria attributable to the chromosomal fosA gene [Internet]. 2017. Available from: 10.","DOI":"10.1128\/mBio.00749-17"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0009","first-page":"217","volume":"2","author":"Casta\u00f1eda-Garc\u00eda","year":"2013"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0010","volume":"66","author":"Zheng","year":"2022"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0011","series-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically : approved standard","first-page":"65","author":"Wikler","year":"2009"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0012","unstructured":"Committee T.E., Testing A.S., Changes C., Guidance N., Breakpoint E., Dosages T., et al. European Committee on Antimicrobial Susceptibility Testing breakpoint tables for interpretation of MICs and zone diameters. 2023."},{"issue":"1","key":"10.1016\/j.diagmicrobio.2025.117110_bib0013","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1128\/AAC.01235-09","article-title":"In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and\/or colistin","volume":"54","author":"Endimiani","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2025.117110_bib0014","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1128\/JCM.03484-13","article-title":"Fosfomycin susceptibility in carbapenem-resistant enterobacteriaceae from Germany","volume":"52","author":"Kaase","year":"2014","journal-title":"J Clin Microbiol"},{"issue":"6","key":"10.1016\/j.diagmicrobio.2025.117110_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/antibiotics12060971","article-title":"The use of intravenous fosfomycin in clinical practice: a 5-year retrospective study in a tertiary hospital in Italy","volume":"12","author":"Anastasia","year":"2023","journal-title":"Antibiotics"},{"issue":"JUN","key":"10.1016\/j.diagmicrobio.2025.117110_bib0016","article-title":"In vitro pharmacokinetics\/pharmacodynamics evaluation of fosfomycin combined with amikacin or colistin against KPC2-producing Klebsiella pneumonia","volume":"7","author":"Yu","year":"2017","journal-title":"Front Cell Infect Microbiol"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2025.117110_bib0017","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1093\/cid\/ciz181","article-title":"Fosfomycin for injection (ZTI-01) versus piperacillin-tazobactam for the treatment of complicated urinary tract infection including acute pyelonephritis: ZEUS, A phase 2\/3 randomized trial","volume":"69","author":"Kaye","year":"2019","journal-title":"Clinic Infect Dis"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2025.117110_bib0018","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01424-17","article-title":"Inhibition of fosfomycin resistance protein FosA by phosphonoformate (foscarnet) in multidrug-resistant gram-negative pathogens","volume":"61","author":"Ito","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0019","doi-asserted-by":"crossref","unstructured":"Elliott Z.S., Barry K.E., Cox H.L., Stoesser N., Carroll J., Vegesana K., et al. The role of fosA in challenges with Fosfomycin susceptibility testing of multispecies Klebsiella pneumoniae carbapenemase-producing clinical isolates [Internet]. 2019. Available from: 10.","DOI":"10.1128\/JCM.00634-19"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2025.117110_bib0020","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.ijantimicag.2016.08.013","article-title":"Characterisation of fosfomycin resistance mechanisms and molecular epidemiology in extended-spectrum \u03b2-lactamase-producing Klebsiella pneumoniae isolates","volume":"48","author":"Lu","year":"2016","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0021","article-title":"Transporter genes and fosA associated with Fosfomycin resistance in carbapenem-resistant Klebsiella pneumoniae","volume":"13","author":"Wang","year":"2022","journal-title":"Front Microbiol"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0022","doi-asserted-by":"crossref","unstructured":"Peirano G., Chen L., Kreiswirth B.N., Pitout J.D.D. Emerging antimicrobial-resistant high-risk Klebsiella pneumoniae clones ST307 and ST147 [Internet]. 2020. Available from: https:\/\/bigsdb.pasteur.fr\/klebsiella\/.","DOI":"10.1128\/AAC.01148-20"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0023","unstructured":"Lewis J., Weinstein M., Melvin B., Campeau S., Cullen S., Galas M., et al. CLSI M100 ED32_2022.Pdf. 2022."},{"issue":"22","key":"10.1016\/j.diagmicrobio.2025.117110_bib0024","doi-asserted-by":"crossref","first-page":"6968","DOI":"10.1128\/JB.00748-09","article-title":"The glycerol-3-phosphate permease GlpT is the only fosfomycin transporter in Pseudomonas aeruginosa","volume":"191","author":"Casta\u00f1eda-Garc\u00eda","year":"2009","journal-title":"J Bacteriol"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2025.117110_bib0025","doi-asserted-by":"crossref","DOI":"10.1128\/msphere.00651-22","article-title":"Molecular mechanisms of resistance to Ceftazidime\/avibactam in clinical isolates of enterobacterales and Pseudomonas aeruginosa in Latin American hospitals","volume":"8","author":"Mojica","year":"2023","journal-title":"mSphere"},{"issue":"SUPPL. 1","key":"10.1016\/j.diagmicrobio.2025.117110_bib0026","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.ijantimicag.2007.06.015","article-title":"Pseudomonas aeruginosa bloodstream infections: how should we treat them?","volume":"30","author":"van Delden","year":"2007","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.diagmicrobio.2025.117110_bib0027","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ijantimicag.2009.03.009","article-title":"Fosfomycin for the treatment of infections caused by multidrug-resistant non-fermenting gram-negative bacilli: a systematic review of microbiological, animal and clinical studies","volume":"34","author":"Falagas","year":"2009","journal-title":"Int J Antimicrob Agent"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325004328?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889325004328?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T03:25:59Z","timestamp":1773113159000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889325004328"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S0732889325004328"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.117110","relation":{},"ISSN":["0732-8893"],"issn-type":[{"value":"0732-8893","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High in vitro activity of Fosfomycin in carbapenemase-producing Klebsiella pneumoniae and carbapenem-resistant Pseudomonas aeruginosa in clinical isolates in Colombia","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2025.117110","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117110"}}